This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Two-Year Outcomes of the Five-Year SMART Trial, presented at CRT 2025. Reardon, M.D., Additional findings at five years include: Numerically lower rate of cardiovascular mortality (7.2%
IntroductionPercutaneous balloon valvuloplasty is the treatment of choice for critical pulmonary valve stenosis (CPS) and pulmonary valve atresia with intact ventricular septum (PA/IVS) if the ventricle has a suitable size. The Z-scores of pulmonary valve diameter, balloon/annulus ratio, number of cusps, and persisting stenosis were analyzed.
The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.
Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV). Forty-seven received SEVs using COL, and 50 with CON techniques.
How does diffuse interstitial myocardial fibrosis, as observed on cardiac magnetic resonance (CMR), correlate with clinical outcomes in moderate and asymptomatic severe aortic stenosis (AS)?
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4
We aimed to quantify the impact of health system disruptions during the COVID-19 pandemic, on their clinical outcomes and whether these differed by socioeconomic and ethnic subgroups. Outcomes did not vary by pandemic birth era according to social characteristics.
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. Perivalvular thrombus has also been reported. had thrombus at any aortic valve complex.
(MedPage Today) -- Submaximal balloon angioplasty for symptomatic intracranial atherosclerotic stenosis (ICAS) improved outcomes over aggressive medical management alone, the BASIS trial from China showed. The incidence of the composite of any.
(MedPage Today) -- People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aortic stenosis (AS) fared particularly poorly in a large cohort study, which researchers said calls for awareness and timely treatment. Compared with AS alone.
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
What is the prevalence and what are the survival outcomes of patients with discordant high-gradient aortic stenosis (DHG-AS; defined as mean gradient [MG] ≥40 mm Hg and effective orifice area [EOA] >1.0
What is the change in incidence, clinical presentation, treatment, and outcome for quantitatively defined severe aortic stenosis (AS) over the last 20 years in a population-based community?
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure.
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. Circulation: Cardiovascular Interventions, Ahead of Print.
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
Initial suspicion of underlying ICAD could help in the early adoption of rescue techniques, reducing the total number of passes and increasing the chances of sustained final recanalization and favorable outcomes. Bailout strategies were required more often in the IS+ group (34.6% Vs12.8%; p=0.001), and procedural times were longer (56.6
Patients with severe aortic stenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aortic valve replacement (AVR). The timing and magnit.
Bicuspid aortic valve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aortic stenosis and/or regurgitation, and is often associated with aortic root dilation.
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. P=0.011) and composite outcome (hazard ratio, 1.64;P<0.001). Subgroups were based on MR severity (severe and nonsevere). P<0.001).
Aortic stenosis (AS) due to fibrosis and calcification of the aortic valve is a hazardous component of cardiovascular disease burden—after developing symptomatic AS, patients survive for an average of less than 2 years without treatment.
In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.
IntroductionPrimary pulmonary vein stenosis (PVS) is a rare congenital heart disease that proves to be a clinical challenge due to the rapidly progressive disease course and high rates of treatment complications.
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. 23), which was not associated with better/worse clinical outcomes in patients with prior CABG.
We defined high-risk post-EVT stenosis as any stenosis with 50% lumen stenosis, associated dissection, re-occlusion during thrombectomy, and severe residual luminal irregularity. Conclusions:Eptifibatide use is associated with lower re-occlusion rates in patients with residual high-risk stenosis after EVT.
Nonmalignant tracheal stenosis is a potentially life threatening conditions that develops as fibrotic healing from intubation, tracheostomy, caustic injury or chronic infection processes like tuberculosis.
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Sarcopenia is an independent predictor of short-term and long-term outcomes after TAVR and should be incorporated as a prognostic marker in preprocedural planning.
The red arrow shows a roughly 80% stenosis of the proximal LAD. The blue arrow shows another stenosis of the LAD distal to the first diagonal branch of about 99%. The green arrow shows a 95% stenosis of the ostium of the first diagonal branch. Image 2: This is the LAO cranial projection.
BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. Journal of the American Heart Association, Ahead of Print. In multivariate analysis, low CCDR (hazard ratio, 2.21 [95% CI, 0.99–4.92],P=0.04)
Background:Postoperative complication rates of carotid endarterectomy (CEA) and carotid artery stenting (CAS) for carotid artery stenosis are recommended to be maintained below a certain threshold. This study indicates the importance of considering surgical volume as a factor to improve outcomes of CEA and CAS in Japan.
However, the long-term outcomes in patient with an intermediate stenosis received FFR have not yet been investigated comprehensively.Methods:We retrospective included 558 patients underwent both coronary artery angiography (CAG) and FFR.
Yasser Sammour, MD, MScpresented "Long-Term Hemodynamic Performance and Clinical Outcomes in Small and Large Aortic Annuli Patients with Severe Aortic Stenosis."This The association of BVD with clinical outcomes (unadjusted for covariates) was evaluated by small and large annuli (CT annular diameter 23 vs >23 mm).
Background and Purpose:We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type-9 inhibitor for intensive lipid-lowering, on intracranial atherosclerotic stenosis (ICAS).Methods:From The primary outcomes were the percentage change in plaque burden and plaque response (plaque regression >5%) rate.
Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)
Introduction Congenital tracheal stenosis (CTS) is a rare but life-threatening disease that can lead to respiratory dysfunction in children. Computational fluid dynamics was used to compare the outcomes of different sequences. Both of the diseases require surgical intervention.
A new study demonstrates parity between a minimally invasive procedure to replace the aortic valve in the heart—transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR).
BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
Non-rheumatic aortic stenosis (AS) is among the most common valvular diseases in the developed world. In this review, we discuss the current understanding of moderate AS, including the epidemiology, current surveillance and management guidelines, clinical outcomes, and future studies.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content